匹多莫德联合伐昔洛韦对玫瑰糠疹患者T淋巴细胞亚群的影响

摘要

目的：探讨匹多莫德联合伐昔洛韦对玫瑰糠疹患者T淋巴细胞亚群的影响。方法选择2012年5月至2015年8月渭南市中心医院接诊的90例玫瑰糠疹患者为研究对象，按照随机数字表法分为观察组和对照组，各45例。对照组患者口服伐昔洛韦片，每次0.3 g，每日2次；观察组在对照组的基础上口服匹多莫德片，每次0.4 g，每日2次。1个月为1个疗程，两组患者均连续服用两个疗程。对比分析两组患者治疗前后T淋巴细胞亚群的变化，疗效及其不良反应情况。结果治疗后，观察组CD3＋、CD4＋、CD4＋／CD8＋高于对照组[（73.01±5.43）％比（63.88±5.31）％，（41.58±2.43）％比（33.12±2.31）％，1.51±0.02比1.08±0.01]，CD8＋低于对照组[（26.12±3.02）％比（31.68±3.10）％]，两组比较差异有统计学意义（P ＜0.01）。观察组患者总有效率高于对照组[97.8％（44／45）比48.9％（22／45）]，总不良反应发生率低于对照组[4.4％（2／45）比44.4％（20／45）]，差异有统计学意义（P＜0.05）。结论匹多莫德联合伐昔洛韦对玫瑰糠疹效果良好，不良反应发生率低，对T淋巴细胞亚群失常有很好的调节作用。%Objective To study the effect of pidotimod combined with valaciclovir therapy on T lympho-cyte subsets of patients with pityriasis rosea.Methods Total of 90 cases of pityriasis rosea in Weinan Cen-tral Hospital from May 2012 to Aug.2015 were included in the study.They were divided into an observation and a control groups according to the random number table method,45 cases in each group.The control group was treated with valaciclovir tablets,oral,0.3 g/time,2 times/day;the observation group was treated with pidotimod tablets,oral,0.4 g/times,2 times/day,a month as a treatment course of treatment,both groups were treated for two courses.The T-lymphocyte subsets changes of the two groups were compared.Results CD3+,CD4+,CD4+/CD8+of the observation group were higher than the control group after treatment[(73.01 ±5.43)% vs (63.88 ±5.31)%,(41.58 ±2.43)% vs (33.12 ±2.31)%,(1.51 ±0.02) vs (1.08 ± 0.01)],CD8+was lower the control group[(26.12 ±3.02)%vs (31.68 ±3.10)%],with statistically sig-nificant differences( P<0.01) .the total effective rate of the observation group was higher than the control group[97.8(44/45)% vs 48.9(22/45)%],the total adverse reaction rate of the observation group was lower than the control group[4.4(2/45)%vs 44.4(20/45)%],the differences were statistically significant ( P <0.05 ) .Conclusion Pidotimod combined with valacyclovir treatment for pityriasis rosea has good effect,low incidence of adverse reactions,with a very good regulation of T lymphocyte subsets disorders.